SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending as investors react to CEO Mark Zuckerbergs upcoming product roadmap in London and high-profile praise from NVIDIAs CEO regarding the company's efficient AI monetization. The community remains sharply divided between those viewing the stock as an undervalued AI leader with strong ad revenue growth and skeptics who are wary of its massive capital expenditures and persistent price volatility.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom shares are under heavy selling pressure after management maintained their AI revenue guidance rather than raising it to meet the market's elevated expectations. While community sentiment remains split between long-term investors viewing the dip as an accumulation opportunity and traders worried that the AI momentum trade is finally losing its steam.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is trending due to significant insider buying, which has sparked optimism among investors viewing the stock as oversold and ripe for a rebound. The community remains deeply divided, with some pointing to robust brand presence and growth potential while others warn of intense competition and market manipulation.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is experiencing heightened volatility as retail and institutional investors debate the sustainability of its recent parabolic run, fueled by AI infrastructure hype and speculation surrounding potential S&P 500 index inclusion. While the community is sharply divided between those calling for a structural correction due to valuation concerns and those anticipating a continued squeeze driven by massive institutional demand, the stock remains a primary focal point for market participants watching for signs of sector-wide fatigue.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon shares are currently trending as investors debate whether the recent settlement with founder Chip Wilson and ongoing insider buying signal a bottom or further downside. The community remains polarized, with many buyers viewing the stock as a deeply undervalued long-term growth opportunity despite broader retail sector headwinds and concerns over upcoming earnings.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is facing intense downward pressure and fresh 52-week lows as investors express frustration with management, inconsistent portion sizes, and a perceived decline in brand value. While some in the community see the current price as a potential value opportunity or an attractive long-term accumulation point, others are aggressively betting against the stock, citing ongoing margin compression and the broader struggle of consumer-facing brands in the current economic environment.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T is trending due to a significant $250 billion commitment toward expanding U.S. connectivity infrastructure, including fiber, 5G, and satellite initiatives. Investors are actively debating whether this massive long-term capital allocation will successfully drive future growth and network resilience or if it will be overshadowed by persistent competitive pressures and debt management concerns.

Ciena Corp. is a network technology company, which engages in the provision of hardware, software, and services to network operators, as well as enabling enhanced network capacity, service delivery, and automation. It operates through the following segments: Networking Platforms, Platform Software and Services, Blue Planet Automation Software and Services, and Global Services. The Networking Platforms segment consists of converged packet optical and packet networking portfolios. The Platform Software and Services segment provides analytics, data, and planning tools to assist customers in managing its networking platforms products. The Blue Planet Automation Software and Services segment enables customers to implement large-scale software and IT-led OSS transformations by transforming legacy networks into service ready networks. The Global Services segment offers a broad suite of value-added services. The company was founded by Patrick H. Nettles and Kevin Brian Kimberlin in 1992 and is headquartered in Hanover, MD.

CIENA Corp.

Ciena is experiencing significant momentum and investor interest driven by strong AI-related demand for optical networking infrastructure and a robust order backlog. The community is actively discussing the stock's parabolic trajectory and debating whether current valuations are justified by the ongoing multi-year AI hardware buildout cycle.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is attracting significant investor attention following the announcement of a major multi-year cloud computing agreement, though shares faced high volatility as traders debated whether this contract and the upcoming Northern Data acquisition justify the current valuation or invite further short-selling pressure. The community is actively discussing the stock's potential as an AI infrastructure player, closely monitoring the influence of Tether's backing and the ongoing battle between long-term bullish holders and high short interest.

LifeVantage Corp. engages in the identification, research, development, formulation, and sale of nutraceutical dietary supplements and personal care products. Its products include Protandim, Axio, TrueScience, PhysIQ, and Petandim. It operates through the Americas, and Asia or Pacific and Europe geographical segments. The company was founded in June 1988 and is headquartered in Lehi, UT.

Lifevantage Corporation

Lifevantage Corporation is gaining significant investor attention due to a high-conviction short squeeze setup characterized by extremely high cost-to-borrow fees and limited share availability. The community is actively tracking these tightening liquidity conditions, with many investors debating the potential for a sharp price movement as short sellers face mounting pressure to cover their positions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Multi-Billion-Dollar Race to Defeat Glioblastoma: Why Investors Are Watching One of Oncology's Most Challenging Frontiers

Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. $NTHI, $KZIA, $BNTX, $IBRX

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2, 2026, in Chicago. The presentations span two randomized...

IBRX and the BCG Shortage: Deals That Could Expand Demand

ImmunityBio targets the BCG shortage with new supply deals and label expansion efforts that could strengthen Anktiva demand in bladder cancer.

IBRX Stock Outlook After Q1 Results and a New FDA Review

ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.

ImmunityBio: Anktiva Explained and What Comes Next

IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.

The $13 Million Company Teaching the Immune System to Hunt Cancer

The $13 Million Company Teaching the Immune System to Hunt Cancer The $13 Million Company Teaching the Immune System to Hunt Cancer PR Newswire NEW YORK, May 29, 2026 Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)Three drugs in human trials. A platform licensed from one of the world's top...

ImmunityBio Deadline Today: Rosen Law Firm Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the Class Period), of the important May 26, 2026 lead plaintiff deadline in the securities class action...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX PR Newswire NEW YORK, May 26, 2026 NEW YORK, May 26, 2026...

IBRX FINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ImmunityBio, Inc. (ImmunityBio or the Company) (NASDAQ: IBRX) and reminds investors of the May 26, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has...

IBRX DEADLINE ALERT: ImmunityBio (IBRX) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action -- Hagens Berman

IBRX DEADLINE ALERT: ImmunityBio (IBRX) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action -- Hagens Berman IBRX DEADLINE ALERT: ImmunityBio (IBRX) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action -- Hagens Berman PR Newswire SAN...

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRX Says ANKTIVA Delivers Up To $314K Cost Advantage Over J&J's TAR-200 — Everything To Know About ImmunityBio’s Findings

Equity

Bearish Sentiment

Retail investors are highly focused on patient advocacy testimonies regarding the drug Anktiva for priority voucher consideration.

Community discussions are buzzing with claims that institutional investors and big pharma are suppressing the share price through manipulation.

Investors express strong conviction in the therapeutic breakthroughs of the company's leading cancer treatment platform.

Long-term bulls are viewing recent volatility and the sub-$7 price range as prime accumulation zones for savvy shareholders.

IBRXImmunityBio Inc

Fundamentals

Feed

News

Sentiment

Fundamentals

Info

Latest IBRX News